Cerebral sites of central action of dermorphin on intestinal motility in the rat.
Dermorphin (DM), microinjected at 0.4 nmoles/rat into various sites of the periaqueductal gray matter (PAG), provokes complete inhibition of intestinal propulsion always coupled with full analgesia and catalepsy. When electrolytic lesions were made in the raphe magnus nucleus (NRM) a slight but significant reduction of intestinal inhibition evoked by DM into the PAG was observed. In contrast, pretreatment into the NRM 10 days before DM with a selective antiserotoninergic agent (5,6 DHT 15 microgram/rat), did not influence intestinal inhibition. As expected, both lesions reduced DM-induced analgesia but catalepsy was not affected. DM-induced inhibition of intestinal transit was therefore unaffected by subdiaphragmatic vagotomy. Finally, some other central brain regions were found sensitive to DM for the above effects such as the lateral and medial hypothalamus and mid-line thalamus. Negative results were obtained for the supraoptic nuclei and postero-medial cortical amygdaloid nucleus. Some considerations are put forward about the existence in the central nervous system of selective areas involved in intestinal modulation and their relationship with those mediating other opiate behavioural effects.
D000679:Amygdala / Q000187:drug effects; D000700:Analgesics; D000818:Animals; D001931:Brain Mapping; D002375:Catalepsy / Q000139:chemically induced; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007031:Hypothalamus / Q000187:drug effects; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology*; D018847:Opioid Peptides; D010487:Periaqueductal Gray / Q000187:drug effects*; D051381:Rats; D012701:Serotonin / Q000502:physiology; D013787:Thalamic Nuclei / Q000187:drug effects; D014630:Vagus Nerve / Q000502:physiology
D000700:Analgesics; D009842:Oligopeptides; D018847:Opioid Peptides; C030058:dermorphin; D012701:Serotonin